Fresh2 (FRES): Utang-utang marang kapitalisasi buku

Tandha merek fresh2.co (FRES)

Fresh2 Group Limited is developing a digital medical diagnostics ecosystem, expanding its revenue base through IT services for clinics. The company optimizes agrologistics via data, connecting farmers with restaurants, and adheres to fundamental back-office environmental standards. The company's total debt-to-equity ratio confirms these foundations, where 0.00 represents the current metric level, demonstrating a balance between financial stability and profitability.

FRES Rasio utang marang nilai buku Fresh2 Group (21.02.2024 - 04.01.2025)
Produk asli Fresh2 Group Ltd

Fresh2 Group Limited operates in the high-tech B2B supply segment subject to strict regulatory control. This metric compares total liabilities to equity, reflecting the share of debt financing within the balance sheet structure. It determines the business's level of dependence on creditors and the risk of default during market volatility. The company's proprietary IT platform creates a sustainable barrier for competitors, reducing operational risks. By analyzing the financial stability indicator—debt-to-capitalization—an investor assesses the balance between security and the use of leverage for expansion.

Pesaing Fresh2 Group Limited

A - Utang-utang marang kapitalisasi buku|Rasio utang marang nilai buku questdiagnostics.com DGX|Illumina - Utang-utang marang kapitalisasi buku|EXAS: Utang-utang marang kapitalisasi buku|Rasio utang marang kapitalisasi buku PerkinElmer|Bio-Rad Corp (BIO) - Rasio utang marang nilai buku|NNNN (Anbio Biotechnology) - Utang-utang marang kapitalisasi buku|Utang-utang marang kapitalisasi buku SHC|Rasio utang marang kapitalisasi buku QuidelOrtho Corporation (QDEL)|Rasio utang marang kapitalisasi buku OPKO Health Inc OPK|CDNA: Utang marang nilai buku|Maravai - Utang-utang marang nilai buku|Rasio utang marang kapitalisasi buku FLGT (Fulgent Genetics, Inc.)|LAB - Utang-utang marang aset resik|Cytek Biosciences - Utang-utang marang kapitalisasi buku|OSUR (OraSure Technologies, Inc.) - Utang-utang marang aset resik|XGN: Rasio utang marang kapitalisasi buku|Utang-utang marang aset resik MDxHealth, Inc.|LUCD - Utang-utang marang kapitalisasi buku|Rasio utang-utang marang kapitalisasi buku PRE (prenetics.com)|Rasio utang marang kapitalisasi buku Insight Molecular Diagnostics Inc|Rasio utang marang aset resik Trinity Biotech PLC TRIB|PRPH (ProPhase) - Utang-utang marang kapitalisasi buku|AIMD: Utang-utang marang nilai buku|Co-Diagnostics, Inc. - Rasio utang marang kapitalisasi buku|heartsciences.com (HSCS) - Utang-utang marang aset resik|BMRA - Utang-utang marang kapitalisasi buku|Rasio utang marang aset resik CDIO|Rasio utang marang kapitalisasi buku VRAX (Virax Biolabs Group Ltd)|BJDX (Bluejay Diagnostics Corp) - Utang marang nilai buku|Rasio utang marang aset resik AWH (Aspira Women's Health)|Utang-utang marang kapitalisasi buku acceleratediagnostics.com|CNTG - Utang marang aset resik|Rasio utang marang kapitalisasi buku ENZ (Enzo Biochem, Inc.)|gtglabs.com (GENE) - Rasio utang marang aset resik|Rasio utang marang kapitalisasi buku 23andMe Inc (ME)|Utang-utang marang nilai buku PMD